EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Toxoplasma gondii as a potential modifier of schizophrenia risk: Epidemiological evidence, mechanisms and candidate biomarkers

Mateusz Gumienny, Nikodem Świderski

Przeglad Epidemiologiczny · 19.11.2026

DOI: 10.32394/pe/242867 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Przeglad Epidemiologiczny, online erschienen am 19.11.2026. Verfasst von Mateusz Gumienny und 1 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Schizophrenia is a multifactorial psychiatric disorder in which environmental exposures, including infections, interact with genetic vulnerability. Among neurotropic pathogens, the intracellular protozoan parasite Toxoplasma gondii has attracted particular attention because of its ability to establish chronic cysts in the brain and to manipulate host behavior in animals. Epidemiological studies consistently report higher seroprevalence of T. gondii among patients with schizophrenia compared with controls, especially in early stages of psychosis. Experimental, animal, and bioinformatic studies have proposed several mechanisms through which Toxoplasma gondii exposure or chronic infection could plausibly be related to neurobiological processes relevant to schizophrenia. This narrative review synthesises current evidence on the molecular pathways linking T. gondii infection to schizophrenia, with a particular focus on mechanisms amenable to therapeutic modulation and on candidate biomarkers proposed to stratify infected individuals, none of which has yet been validated as a predictor of schizophrenia risk. PubMed and related databases were searched for clinical, experimental, and in silico studies examining T. gondii, schizophrenia, molecular or immunological mechanisms, and biomarkers up to February 2026. The literature most consistently supports an epidemiological association between T. gondii seropositivity and schizophrenia. Proposed mechanistic links – including kynurenine-pathway alterations, glial activation, molecular mimicry, neurotransmitter dysregulation, and T-cell changes – are supported to varying degrees by animal, in vitro, biomarker, and computational studies, but remain insufficiently validated as causal pathways in humans. Exploratory candidate biomarkers, none yet validated in humans as predictors, include refined serological measures (e.g. antibodies to the cyst matrix antigen MAG1, studied mainly in mice, and serotype-specific responses), autoantibodies to NMDAR, kynurenine pathway metabolites, neurobiological and immune serum markers (KLK6, UCHL1, neurogranin, IL‑10, IL‑8, MIP‑1β), markers of neuronal injury and innate immune activation (neuron‑specific enolase, IL‑18), and hair glucocorticoid levels.

Zitieren

APA

Gumienny, M., & Świderski, N. (2026). Toxoplasma gondii as a potential modifier of schizophrenia risk: Epidemiological evidence, mechanisms and candidate biomarkers. Przeglad Epidemiologiczny. https://doi.org/10.32394/pe/242867

Vancouver

Gumienny M, Świderski N. Toxoplasma gondii as a potential modifier of schizophrenia risk: Epidemiological evidence, mechanisms and candidate biomarkers. Przeglad Epidemiologiczny. 2026. doi:10.32394/pe/242867

BibTeX
@article{Gumienny2026,
  author = {Gumienny, Mateusz and Świderski, Nikodem},
  title = {Toxoplasma gondii as a potential modifier of schizophrenia risk: Epidemiological evidence, mechanisms and candidate biomarkers},
  journal = {Przeglad Epidemiologiczny},
  year = {2026},
  doi = {10.32394/pe/242867}
}
Kostenlos starten →